PX 12

Drug Profile

PX 12

Alternative Names: IV 2 compound; IV-2; PX-12; thioredoxin inhibitor PX-12; thioredoxin-1 inhibitor PX-12

Latest Information Update: 30 Dec 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Arizona
  • Developer National Cancer Institute (USA); Oncothyreon; ProlX Pharmaceuticals; Translational Genomics Research Institute
  • Class Antineoplastics; Disulfides; Imidazoles; Small molecules
  • Mechanism of Action Thioredoxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • No development reported Cancer; Gastrointestinal cancer; Pancreatic cancer

Most Recent Events

  • 11 Jun 2008 Phase-Ib clinical trials in advanced or metastatic Cancer in USA (IV)
  • 16 Apr 2008 Pharmacodynamics data from phase I trials in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
  • 30 Jan 2008 PX 12 is still in phase II trials for advanced Pancreatic cancer in the USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top